[go: up one dir, main page]

WO2002007728A1 - Prevention de la chute des cheveux - Google Patents

Prevention de la chute des cheveux Download PDF

Info

Publication number
WO2002007728A1
WO2002007728A1 PCT/US2001/007422 US0107422W WO0207728A1 WO 2002007728 A1 WO2002007728 A1 WO 2002007728A1 US 0107422 W US0107422 W US 0107422W WO 0207728 A1 WO0207728 A1 WO 0207728A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
testosterone
active compound
blocker
minoxidil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/007422
Other languages
English (en)
Inventor
W. Roy Knowles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP01913352A priority Critical patent/EP1313479A4/fr
Priority to JP2002513463A priority patent/JP2004538243A/ja
Priority to AU2001242024A priority patent/AU2001242024A1/en
Publication of WO2002007728A1 publication Critical patent/WO2002007728A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • Hair bulbs are responsible for normal, healthy hair growth and retention. Hair bulbs are located in the skin, about 3/16 of an inch below the skin surface. They are located just above the fatty layer at the very lower most position of the skin.
  • DHT 5 ⁇ -dihydrotestosterone
  • DHT is produced by reducing testosterone with a 5 ⁇ -reductase enzyme.
  • the phenotypic expression of baldness does not occur in the absence of testosterone.
  • 7Androgenic alopecia or common baldness represents 99 percent of all cases of hair loss.
  • Broadland, id. The mechanism through which androgens regulate the biology of hair is by modulating the hair growth cycle. Ebling, 4 Biochem. Soc. Trans. 597; Bergfield et al . , 5 Dermatol. Clin. 491.
  • the effect of DHT on hair growth appears to be related to local rather than systemic levels of the hormone. This is because the capacity of scalp skin from balding individuals to convert testosterone ("T") to DHT is greater than that observed in the scalp of non-balding individuals.
  • Hair Loss Prevention Hair loss prevention preparations are known in the art. These include natural product preparations, biological products, vascular toners and testosterone blockers . Several prior art compositions are discussed in the accompanying Petition To Make Special and its accompanying references, the contents of which are incorporated herein by reference. Natural Products . Several inventors disclose natural compositions. Casero, United States Letter Patent No. 5,340,579, discloses a composition comprising (a) mucopolysaccharides, (b) human umbilical cord extract, (c) tetrahydrofurfuryl nicotinate, and (d) pharmaceutically and cosmetically acceptable excipients. Buck, United States Letter Patent No.
  • 5,512,275 and 5,609,858 discloses a formulation for the treatment of androgenic alopecia, comprising liquor carbonis detergens in combination with spirits of camphor, castor oil, isopropyl alcohol.
  • Chizick et al. United States Letter Patent No. 5 ' , 972,345, discloses a combination of saw palmetto extract, African pygeum extract, and stinging nettle extract.
  • Hoke United States Letter Patent No. 5,994,319 discloses using genetic material as a anti alopecia therapeutic. Hoke proposes using anti-sense oligonucleotides targeting 5- ⁇ reductases in conjunction with other hair growth enhancers. Tien, United States Letter
  • Patent No. 5,574,011 discloses the use of a class of HRH analogs for treating male pattern baldness.
  • Messenger United States Letter Patent No. 6,020,327, discloses administering aromatase inhibitors to treat hair loss.
  • Liao et al. United States Letter Patent No. 5,422,371 and 5,605,929, discloses a class of anti-androgenic compounds.
  • Vascular Toners Several organic chemicals are known to affect, the hair growth and hair retention cycle. These include minoxidil. I refer to minoxidil and similar kinds of compounds as "vascular toners," because they are believed to be effective due to their impact on local blood circulation.
  • Minoxidil has been shown to stimulate hair growth or inhibit the loss of hair in a number of patients beginning to develop androgenic alopecia.
  • Minoxidil is the generic name for 6- (1-piperidinyl) -2, 4-pyrimidinediamaine 3-oxide. Its preparation is disclosed in Anthony, W.C. et al . , United States Letters Patent No. 3,382,247 (1968); McCall, J.M., et al., 40 J. Organic Che . 3304 (1975); Gorecki, D.K.J., 17
  • Minoxidil is medically classified as an anti- hypertensive. It affects heart rate and rhythm. It has thus been used in an oral formulation as a cardiac drug. Andersson, 0., 205 Acta Med. Scand. 213 (1979); Moser, M., 26 Advan. Cardiol. 38 (1979) . Over dosage may create cardiac arrhythmias or other adverse side effects. See e.g., Carlson, E.S., 39 Toxicol. Applied Pharmacol. 1 (1977).
  • Minoxidil is also medically classified as an anti- alopecia agent. Its efficacy in treating early male pattern baldness has been described in numerous published articles. E. g. , Olsen, E.A. et al . , 13 J. Am. Acad. Dermatol. 185 (1985); Novak, E., 24 Int. J. Dermatol. 82 (1982). Its limited percutaneous absorption and secretion is described in Franz, J.T., 121 Arch. Dermatol. 203 (1985).
  • minoxidil alters the hair growth cycle is uncertain. It is thought to act by increasing vascular circulation to the hair follicle. It is known that minoxidil effectiveness is more pronounced in scalp areas which are more vascular.
  • Topical minoxidil is know to have certain shortcomings. It is effective in only about eight percent of adult male users. It produces "lanugo, " or baby-type, hair which is relatively thin. Further, and perhaps most significantly, after approximately 30 months of continuous use, minoxidil shows a sharp drop in effectiveness. After about thirty months of use, about half of the new hair growth falls out. Thus, while the user has somewhat more hair than originally, the user has less hair than originally seen.
  • Testosterone Inhibitors Inhibitors of steroid metabolism, particularly those that inhibit the conversion of testosterone to dihydro testosterone, have shown effects on hair cycles, including inhibition of hair loss.
  • One class of enzymes targeted by these inhibitors are the steroid 5- ⁇ reductases .
  • 5 ⁇ -reductase inhibitors have been shown to inhibit hair loss.
  • stump-tail macaque monkeys treated with the 5 ⁇ -reductase inhibitor 17b-N,N, - dimethylcarbamoyl- -methyl- 4-aza- 5a-androstan- 3-one undergo significantly less age related hair loss than untreated monkeys.
  • Ritt aster et al., 65 J. Clin/ Endocrinol. Metab. 188 (1987) Similarly, finasteride, a 5 ⁇ - reductase inhibitor, miniaturizes scalp hair follicles, reversing the balding process.
  • Testosterone blockers are known in the art (I use the term "testosterone blocker” to denote a competitive antiandrogen which inhibits the binding of testosterone or DHT onto its cell surface binding site, rather than a compound which is used to inhibit the reduction of testosterone into DHT.). Also known is their use systemically (orally or intravenously) . As systemic therapeutics, they are known in the art as having a key shortfall: their long term efficacy is compromised by their blocking of the androgenic feedback inhibition of gonadotropin secretion. This interference results in elevated gonadotropin secretion, which in turn increases testicular secretion of testosterone. The higher level of testosterone eventually overcomes the action of the antiandrogen. Liao, supra, at col. 3, lines 16-31.
  • My invention is a new combination of already known types of compounds .
  • My invention can be used either cosmetically (to maintain healthy hair growth) or pharmaceutically (to treat a medical condition) . It can be made using components already known in the art, allowing one to enjoy the predictability of use available with these old compounds.
  • My invention is flexible enough, however, to also allow one to substitute newly-discovered compounds substantially equivalent to the already known compounds. Thus, my invention can be adapted to allow the user to use the safest, most effective components then available.
  • the penetration enhancer delivers these compounds to the hair bulb, where the compounds are most needed.
  • testosterone blockers if applied topically (rather than syste ically administered) , are effective in preventing hair loss, and if used in conjunction with a dermal penetration enhancer.
  • Such topical use avoids precipitating the systemic increase in testosterone production seen with oral administration, by minimizing systemic interference with normal gonadotropin secretion.
  • vascular toners if applied topically in conjunction with a dermal penetration enhancer, work much better.
  • My invention includes a skin penetration enhancer used together with a testosterone blocker or a vascular enhancer, or both. I first discuss each component individually, and then discuss the combinations of these components that I have found most acceptable. Penetration Enhancers
  • Penetration enhancers and skin penetrating formulations are known in the art. These include the variety of formulations used from time to time for both psoriasis treatment pharmaceuticals, and psoriasis prevention nutritional supplements and cosmetics.
  • the penetration enhancer (or penetration agent) should be accepted for human use by relevant government agencies. .
  • dimethyl sulfoxide while within the scope of the claims, is not a preferred penetration enhancer where that compound is not approved for human topical use.
  • the penetration enhancer should not chemically react with any other ingredient to impair or alter the composition's stability and shelf life. Thus, one should examine the possible reactivity of a given penetration enhancer with a given testosterone blocker or vascular toner.
  • the penetration agent should be cosmetically acceptable. Thus, while I have tested dimethyl acetate, I do not favor it. While it is within the scope of the claims, it is a weak penetration enhancer. Thus, one needs to use a lot of it. In these high amounts, it smells bad. In contrast, methyl acetate is odorless, and I have tested and found it acceptable.
  • liposome technology to deliver cosmetic and dermatology materials. See, for example, Lishko et al., United States Letter Patent No. ⁇ 5,753,263, discloses using liposomes to selectively deliver a composition to hair follicles. Liposomes are made of fatty material, and are suitable for delivering homogenous types of materials. As such, it may be difficult for a liposome to in fact work with a combination of a polar compound (like a minoxidil vascular toner) and a non-polar compound (such as a progesterone testosterone blocker) . I thus do not consider liposome technology within the scope of the term "penetration enhancer" in this patent.
  • vacular Toners like a minoxidil vascular toner
  • a non-polar compound such as a progesterone testosterone blocker
  • My invention works with a variety of vascular toners.
  • a vascular toner if used to maintain healthy function of hair bulbs, must be delivered to .the small blood vessels feeding the hair bulbs . I have thus found that the effectiveness of the vascular toner is greatly improved if it is topically applied along with a penetration enhancer. This allows the vascular toner to act locally.
  • the vascular toner must be carefully titrated against the penetration enhancer. For example, for a given concentration of minoxidil, one needs to use the penetration enhancer in the appropriate concentration. If a given penetration enhancer is used in a too high concentration, the minoxidil may penetrate through the skin and reach the systemic blood circulation. It can there, if present in sufficient amount, cause side effects as seen by taking oral minoxidil. Thus, it is necessary to adjust the amounts of penetration enhancer and vascular toner, depending on the concentration and specific identity of the enhancer and the toner.
  • Adding a penetration enhancer- to the vascular toner appears to fundamentally change the biological mechanism by which the vascular toner works. This is shown by the qualitatively different results seen between minoxidil and my compounds. The two products produce different types of hair, and for different time periods.
  • Minoxidil without a penetration enhancer (as available in ROGAINETM topical minoxidil U.S. P.) produces a different kind of hair than does minoxidil used with a penetration enhancer. It is known in the art that topical minoxidil without a penetration enhancer (as is commercially available in ROGAINE (TM) topical minoxidil U.S. P., commercially available from Pharmacia & Upjohn Inc., Bridgewater, New Jersey) results in thin, baby-like, temporary hair, called “lanugo" hair. I have found that my compounds, by contrast, result in good, coarse, "terminal” hair, hair which is normal, permanent adult hair.
  • Minoxidil without and with penetration enhancer may act on different types of hair bulbs, or produce different responses from the same hair bulbs.
  • Minoxidil without enhancer is only weakly soluble in polar solvents. See supra. It thus has difficulty diffusing to the deeply located hair bulbs (roots) which are located just above the deep fat layer. Minoxidil without enhancer may thus affect only hair bulbs located close to the skin surface, or located in a less fatty skin layer, or hair bulbs most sensitive to changes in blood flow. Alternatively, it may affect the same hair bulbs, but with such weak or attenuated effect that the hair bulbs produce a different type of hair.
  • Minoxidil alone in the concentrations typically used, may actually temporarily alter a normal adult body function (causing the adult body to temporarily produce infant hair) .
  • my invention simply maintains the normal function of the healthy adult body hair bulb, allowing it to continue to produce normal adult hair as long as the compound is used.
  • My invention works with a variety of testosterone blockers. I prefer to use a blocker already approved for human use by the United States Food & Drug Administration, as these types of testosterone blockers, if used in pharmaceutical (as opposed to cosmetic) versions of my invention, do not need to undergo as lengthy and expensive a process to verify their safety and efficacy as used in pharmaceutical products. Examples include flutamide, cyproterone acetate, spironolactone, progesterone, or analogs or derivatives of any of these (e.g., 17-hydroxy-16- methylene- ⁇ 6 -progesterone, 17 ⁇ -hydroxyprogesterone) .
  • testosterone blockers are not actually necessary for my invention to work; minoxidil alone is effective on 8% of patients, while the same amount of minoxidil administered with the proper amount of a penetration enhancer is effective on 35% of patients.
  • testosterone blockers added to such a mix are synergistically beneficial, increasing the efficacy from 35% to 85% of patients.
  • Cioteronel is the common name for hexahydro-4- (5-methoxyheptyl) -2 (1H) -pentalenone. It is also known, or is commercially available, as X-ANDRONTM, CPC-10997, CYOCTOLTM, and EXANDRONTM. It is a clear, colorless oil, soluble in lipid and relatively non-polar solvents. Its preparation is disclosed in Kasha, W.J., PCT Int'l Patent Application 83/04,019 (1983), 101 Chem. Abstr. 23037k (1984). Its use is disclosed in United States Letter Patent No. 4,689,345.
  • testosterone blocker is progesterone, pregn-4-ene-3, 20-dione (commercially available as
  • Progesterone is insoluble in water and soluble n alcohol, acetone, dio ⁇ ane, d concentr ted sulfuric acid. It is sparingly soluble in vegetable oils. Its isolation, structure and biological activity is described at length in Bardin et al. (eds.), Progesterone and Progestins (Raven Press, New York 1982) . I prefer to use progesterone as the sole testosterone blocker.
  • the penetration enhancer""and" the vascular toner or testosterone blocker, or both, may be mixed with a carrier vehicle.
  • a carrier vehicle You can use a variety of vehicles to make my invention.
  • the vehicle is simply a cosmetically safe, medically safe solvent for the active ingredients.
  • the vehicle should not adversely and significantly chemically react with the active ingredients.
  • propylene glyc ⁇ l, water and isopropyl alcohol may be used as vehicles. These may be used alone or in combination.
  • the vehicle can optionally provide functions in addition to simply dissolving, the active ingredients.
  • a moisturizing vehicle or a vehicle containing sunscreen.
  • a moisturizing or moisture retaining vehicle one can use a vehicle made from a combination of (ranked in order of quantity used) wa e * mineral oil, petrolatum, lanolin, sorbitol solution, stearic acid, lanolin alcohol, cetyl alcohol, glyceryl stearate / PEG-100 stearate, triethanolamine, dimethicone, propylene glycol, tri(PPG-3 myristyl ether) citrate, disodium EDTA, methylparaben, ethylparaben, propylparaben, fragrance, xanthan gum, butylparaben, and methyldibromo glutaronitrile.
  • a vehicle containing one or more sunscreens It may be desirable to use a vehicle containing one or more sunscreens. This is because my preparations are used on the tops of balding scalps. Balding scalps are often largely unprotected from sun damage, as the user may not wear headgear and the balding scalp lacks the sun shielding dense hair layer present on a healthy scalp. Adding sunscreen thus can protect the scalp from possible sun damage. Sunscreens, and vehicles containing sunscreen compounds, are widely known in the art. See, e.g. , United States Letter Patent No. 4,522,807.
  • VEHICLE/NTM VEHICLE/N
  • TM VEHICLE/N
  • Vehicle/N (TM) is commercially available from the Neutrogena Dermatologies division of Johnson &
  • VEHICLE/N (TM) ingredients are SD alcohol 40
  • VEHICLE/N (TM) mild ingredients are purified water '(>37.5%), SD alcohol-40
  • VEHICLE/N (TM) is available as 50 mL of vehicle in a plastic bottle with applicator top. The bottle is filled only to 3/4 capacity, to ensure proper mixing. For 50 L of
  • VEHICLE/N use the following amounts:
  • VEHICLE/NTM is available in a bottle with an APPLIDERM (TM) applicator top.
  • the APPLIDERM (TM) applicator unit automatically filters the compounded mixture and provides a convenient, spill-proof, self-contained unit for topical application.
  • To use the APPLIDERM (TM) applicator unit push the applicator firmly into the bottle using the white cap as a holder. Screw the cap all the way down to seat the applicator. Shake well. If tablets are dissolved in the vehicle, then the user should be instructed to allow the solution to stand overnight and to shake vigorously before the first use.
  • VEHICLE/N (TM) should not be used near fire or open flame due to alcohol content.
  • VEHICLE/N (TM) and VEHICLE/N (TM) mild contain substantial alcohol and are not suitable for use in acute dermatoses. Stinging may be noted if used on irritated or abraded skin. Avoid contact with eyes or eyelids. If the product accidentally comes in contact with eyes, rinse thoroughly with water and contact physician. Keep out of reach of children.
  • VEHICLE/N (TM) . and VEHICLE/N (TM) mild are contraindicated in persons who have shown hypersensitivity to any of the listed ingredients.
  • testosterone blockers for the same effect, and may use more or less- of it.
  • Using more testosterone blocker allows one to use relatively less penetration enhancer, or a weaker enhancer. Titration of the two components against one another is a conventional technique well known in the art of pharmaceutical and cosmetics formulation. Such techniques are already used to titrate formulations for the wide variety of trans-dermal drugs and cosmetics currently available.
  • an ethyl alcohol - water - propylene glycol solution may be used as the diluents and vehicle.
  • ethyl alcohol 95% 75.5 cc purified water 18.5 cc propylene glycol 6.0 cc progesterone 1.5 gm minoxidil 2.0 - 5.0 gm methyl acetate 5.0 gtts
  • minoxidil is pharmaceutically and cosmetically effective topically at anywhere from about 0.01 grams to about 50 grams per four ounces, depending on the frequency of topical administration.
  • Testosterone blockers are also pharmaceutically and cosmetically effective topically at anywhere from about 0.01 grams to about- 50 grams per four ounces, depending on the frequency of topical administration. With the higher concentrations, however, increasing the amount of penetration enhancer creates a greater risk of adverse side effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions destinées à prévenir ou réduire la chute des cheveux, permettant au corps de maintenir une croissance normale et saine des cheveux, et comprenant un activateur de pénétration de même qu'un agent de blocage de la testostérone, ou un activateur vasculaire, ou les deux.
PCT/US2001/007422 2000-07-19 2001-03-09 Prevention de la chute des cheveux Ceased WO2002007728A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01913352A EP1313479A4 (fr) 2000-07-19 2001-03-09 Prevention de la chute des cheveux
JP2002513463A JP2004538243A (ja) 2000-07-19 2001-03-09 脱毛症の予防
AU2001242024A AU2001242024A1 (en) 2000-07-19 2001-03-09 Hair loss prevention

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61941200A 2000-07-19 2000-07-19
US09/619,412 2000-07-19

Publications (1)

Publication Number Publication Date
WO2002007728A1 true WO2002007728A1 (fr) 2002-01-31

Family

ID=24481819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007422 Ceased WO2002007728A1 (fr) 2000-07-19 2001-03-09 Prevention de la chute des cheveux

Country Status (4)

Country Link
EP (1) EP1313479A4 (fr)
JP (1) JP2004538243A (fr)
AU (1) AU2001242024A1 (fr)
WO (1) WO2002007728A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750812B2 (en) 2008-09-27 2017-09-05 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2702982T (pt) * 2011-04-25 2017-03-17 Park Jun-Hyoung Composição para aplicação tópica para a prevenção da perda de cabelo e estimulação do crescimento capilar

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
US5183817A (en) * 1981-02-17 1993-02-02 Bazzano Gail S Combinations of retinoids and minoxidil-type compounds for hair growth
US5482965A (en) * 1991-03-19 1996-01-09 Rajadhyaksha; Vithal J. Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active agents
US5994319A (en) * 1996-04-15 1999-11-30 Dyad Pharmaceutical Corporation Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041439A (en) * 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
WO1988005653A1 (fr) * 1987-01-28 1988-08-11 Proctor Peter H Composition a application locale et procede de stimulation de la croissance des cheveux avec des radicaux libres stables
DE3915133C2 (de) * 1987-11-13 2003-04-03 Christoph Luderschmidt Haarwuchsmittel
US5407944A (en) * 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6124362A (en) * 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183817A (en) * 1981-02-17 1993-02-02 Bazzano Gail S Combinations of retinoids and minoxidil-type compounds for hair growth
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5482965A (en) * 1991-03-19 1996-01-09 Rajadhyaksha; Vithal J. Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active agents
US5994319A (en) * 1996-04-15 1999-11-30 Dyad Pharmaceutical Corporation Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1313479A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750812B2 (en) 2008-09-27 2017-09-05 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof

Also Published As

Publication number Publication date
EP1313479A4 (fr) 2005-09-21
AU2001242024A1 (en) 2002-02-05
JP2004538243A (ja) 2004-12-24
EP1313479A1 (fr) 2003-05-28

Similar Documents

Publication Publication Date Title
US6420352B1 (en) Hair loss prevention
US6060070A (en) Isoflavonoids for treatment and prevention of aging skin and wrinkles
US6333057B1 (en) Composition and method for topical treatment of androgenic alopecia
US7879823B2 (en) Topical anti-cancer compositions and methods of use thereof
KR100192734B1 (ko) 칼륨 통로 개방제 및 5알파-환원효소 억제제를 사용하는 모발 성장의 자극 방법
JP2937446B2 (ja) 白髪防止黒化剤
JP2002506821A (ja) 皮膚刺激の治療方法
US5026691A (en) Combination of minoxidil and an antiinflammatory agent for treating patterned alopecia
JP3510751B2 (ja) 美白化粧料
WO1988007361A1 (fr) Combinaison de minoxydil et d'un agent anti-inflammatoire pour le traitement de l'alopecie typique des personnes de sexe masculin
KR100348155B1 (ko) 자연산 상황버섯 추출물을 함유하는 발모제 조성물 및이의 제조방법
WO2002011675A2 (fr) Element nutritif organique destine au traitement de la calvitie
US20060052405A1 (en) Hair loss prevention
JPH11269043A (ja) 頭皮頭髪用化粧料
WO2002007728A1 (fr) Prevention de la chute des cheveux
JPH11269042A (ja) 頭皮頭髪用化粧料
EP0440249A2 (fr) Ethanolamine pour le traitement de la chéloide
JP2002080327A (ja) 養毛料
EP1150671B1 (fr) Composes pyrethroides favorisant la croissance des cheveux
JPH11302131A (ja) 頭皮頭髪用化粧料
KR102386651B1 (ko) 티플락스티닌을 유효성분으로 함유하는 탈모 예방 또는 치료용 조성물
JPH11302133A (ja) 頭皮頭髪用化粧料
EP1898867B1 (fr) Méthode de traitement de troubles de la croissance des cheveux, tels que l alopécie féminine, et préparations employées dans le cadre desdites méthodes
JPH0112725B2 (fr)
US20210106519A1 (en) Formulation and method for the treatment of androgenic alopecia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA IL JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001913352

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001913352

Country of ref document: EP